SCHEMBL269710

SCHEMBL269710

CC(C)CN([C]=O)CC(C)C

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
MAPK1 P28482 1/20 0.36
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL270364 0.86
SCHEMBL270445 0.82 CYP1A2 (0.30) CYP1A2MAPK1
SCHEMBL15903985 0.78 SLC7A5 (0.47) CYP1A2
SCHEMBL11378703 0.78 ALDH1A1 (0.30)
SCHEMBL270909 0.78 TRPM8 (0.31) CA12CA1CA9
SCHEMBL17313808 0.78 CA12 (0.35) CA12CA1CA2CA9
SCHEMBL7822542 0.77 TSHR (0.33)
SCHEMBL277139 0.77
SCHEMBL277438 0.77 ALDH1A1 (0.36) CA12CA1CA2CA9
SCHEMBL276651 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 753 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380197-B1 FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES AVENTIS PHARMA S. A. (FR) 2002-04-30 US claimed
EP-0457195-B1 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1998-04-15 EP claimed
US-5656604-A HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 US claimed
EP-0469889-B1 (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives ZENECA LTD (GB) 1996-01-17 EP claimed
US-5430022-A Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-07-04 US claimed
US-5284828-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 1994-02-08 US claimed
CN-1072461-A The combined extraction method of transuranium element and strontium US ENERGY (US) 1993-05-26 CN claimed
US-5110808-A Aldose reductase inhibitors; peripheral effects of diabetes and galactosemia IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1992-05-05 US claimed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 EP claimed
EP-0334014-A2 Substitued imidazolinones and imidazolethiones BAYER AG (DE) 1989-09-27 EP claimed
EP-0287890-A1 Substituted pyrroles BAYER AG (DE) 1988-10-26 EP claimed
EP-0079467-A1 N-substituted O-pyrazol-4-yl-carbamic-acid esters, process for their preparation and their use as biocides BAYER AG (DE) 1983-05-25 EP claimed
WO-2024128000-A1 ISOPOLYOXOTUNGSTATE SALT COMPOUND, SOLVATE THEREOF OR MIXTURE OF SAID COMPOUND AND SOLVATE, AND METHOD FOR PRODUCING SAID COMPOUND, SOLVATE OR MIXTURE 東京応化工業株式会社 2024-06-20 WO disclosed
WO-2024053650-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST DIACYLGLYCEROL KINASE α AND/OR ζ, AND PHARMACEUTICAL USE THEREOF 小野薬品工業株式会社 2024-03-14 WO disclosed
WO-2024043261-A1 AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME 日本化薬株式会社 2024-02-29 WO disclosed
CN-114026199-B Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof 日本化药株式会社 2023-12-26 CN disclosed
US-4513000-A Insecticidal N-substituted O-pyrazol-4-yl carbamates and use thereof BAYER AKTIENGESELLSCHAFT (DE) 1985-04-23 US disclosed
US-RE31343-E STABILIZERS FOR POLYMERS CIBA-GEIGY CORPORATION (US) 1983-08-09 US disclosed
US-RE31342-E STABILIZERS FOR POLYMERS CIBA-GEIGY CORPORATION (US) 1983-08-09 US disclosed
EP-0079467-A1 N-substituted O-pyrazol-4-yl-carbamic-acid esters, process for their preparation and their use as biocides BAYER AG (DE) 1983-05-25 EP disclosed